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Abstract
Background: The so-called macular carotenoids (MC) lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) comprise
the diet-derived macular pigment (MP). The purpose of this study was to determine effects of MC supplementation
on the optical density of MP (MPOD), repeated-exposure photostress recovery (PSR), and disability glare (DG)
thresholds.
Methods: This was a double-blind, placebo-controlled trial. Fifty-nine young (mean age = 21.7), healthy volunteers
participated in this study. Subjects supplemented their daily diet with either 10 mg L + 2 mg total Z (1 mg Z + 1 mg MZ;
n = 24), 20 mg L + 4 mg total Z (2 mg Z + 2 mg MZ; n = 25), or placebo (n = 10) for 12 months. The primary outcome
was a composite measure of visual performance in glare, defined by change in DG and PSR. Secondary outcomes
included MPOD and visual fatigue. The primary endpoint for outcomes was 12 months. MPOD was assessed with
customized heterochromatic flicker photometry. PSR times for an 8 cycle /degree, 15 % contrast Gabor patch target
were determined after each of five successive exposures to intense LED lights. DG threshold was defined as the intensity
of a ring of lights through which subjects were able to maintain visibility of the aforementioned target. Measures of
all parameters were conducted at baseline, 6 months, and 12 months. Repeated-measures ANOVA, and Pearson
product-moment correlations were used to determine statistically significant correlations, and changes within and
between groups.
Results: MPOD for subjects in both supplementation groups increased significantly versus placebo at both 6- and
12-month visits (p < 0.001 for all). Additionally, PSR times and DG thresholds improved significantly from baseline
compared to placebo at 6- and 12-month visits (p < 0.001 for all). At baseline, MPOD was significantly related to both
DG thresholds (r = 0.444; p = 0.0021) and PSR times (r = -0.56; p < 0.001). As a function of MPOD, the repeated-exposure
PSR curves became more asymptotic, as opposed to linear. The change in subjects’ DG thresholds were significantly
related to changes in PSR times across the study period (r = -0.534; p < 0.001).
Conclusions: Increases in MPOD lead to significant improvements in PSR times and DG thresholds. The asymptotic
shape of the repeated-exposure PSR curves suggests that increases in MPOD produce more consistent steady-state
visual performance in bright light conditions. The mechanism for this effect may involve both the optical filtering and
biochemical (antioxidant) properties of MP.
Trial registration: ISRCTN trial registration number: ISRCTN54990825. Data reported in this manuscript represent
secondary outcome measures from the registered trial.
Keywords: Lutein, Zeaxanthin, Mesozeaxanthin, Visual performance, Photostress recovery, Disability glare, Macular
pigment, Visual cycle
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Background
The dietary carotenoids lutein (L) and zeaxanthin (Z;
3R,3’R-zeaxanthin), along with the zeaxanthin isomer
mesozeaxanthin (MZ; 3R,3’S-zeaxanthin) are found in
high concentrations in the macular retina [1]. Due to
their specific location, they are referred to as the macu-
lar carotenoids (MC); due to their yellow-orange pig-
mentation, they are collectively known as macular
pigment (MP). The location of their respective areas of
deposition is highly specific: L is the dominant caroten-
oid in the peripheral macula, Z in the mid-peripheral
macula and MZ at the center of the macula [1]. The
metabolic demand for oxygen and resulting potential for
oxidative stress is very high in the fovea [2]; the spatial
arrangement of L, Z, and MZ illustrates a relationship
between metabolic demand, which increases dramatic-
ally near the center of the fovea (commensurate with
photoreceptor packing density [3]), and antioxidant cap-
acity. Indeed, MZ is the most potent antioxidant of the
three, followed by Z, which is twice as potent as L in
quenching reactive oxygen species [4]. Given that age-
related macular degeneration (AMD) is attributable at
least in part to oxidative stress, and that irradiation with
short-wavelength light (which MP absorbs) induces oxi-
dative stress in the retina, it has been suggested that the
MCs could prolong the onset or delay the progression of
AMD [5].
In terms of visual performance, the antioxidant poten-
tial of the MCs would appear to impact outcome mea-
sures that are particularly dependent on metabolic
processes, such as dark adaptation [6, 7], contrast sensi-
tivity [8–12], and temporal vision [13, 14]. Due to its
location being anterior to the photoreceptors [15] and
aforementioned yellow-orange coloration [16], most of
the previous work involving macular carotenoids and
visual performance has involved the short-wavelength
filtering properties of MP, however. The filtering proper-
ties of MP have been shown previously to confer visual
performance advantages in terms of visibility through
simulated blue haze [17], chromatic contrast [18], and sev-
eral aspects of visual performance in glare, including vis-
ual discomfort [19, 20], disability glare (DG) [10, 18, 21]
and photostress recovery (PSR) [10, 18, 21]. These effects,
however, appear to be dependent on the presence of an
appreciable short-wavelength component in the glare
source [22], such as that found in the solar spectrum. For
example, a recent investigation of visual performance
after augmentation of MP optical density (MPOD)
with MC supplementation determined significant im-
provements in contrast sensitivity, but not PSR [12].
A bright, tungsten source was used as the photostres-
sor in that study, and may not have contained a suffi-
cient amount of short-wavelength energy to reveal
effects of MP’s filtering.
The purpose of this investigation was to examine more
closely the dynamics of PSR by challenging subjects with
repeated glare exposures (separated by intervening
recovery) within a single trial. This approach allows for
the determination of a ‘visual fatigue’ function that
reveals the impact of MPOD on the recovery of target
visibility over several sequential glare exposures. A func-
tion whose slope is steep would indicate much fatigue
(i.e., increased recovery time required for sequential
exposures), whereas a shallow slope would be indicative
of relatively steady recovery as a function of exposure
trial, and hence relatively little fatigue. DG thresholds
for a fine spatial grating were also determined, and com-
pared to slopes and absolute recovery times for the PSR
portion of the study. Finally, the use of a supplement
that contains all three macular carotenoids would pre-
sumably have the strongest impact on MPOD, and
(based on previous investigations [18, 21]) would there-




This study was reviewed and approved by the University
of Georgia Institutional Review Board. Informed consent
was obtained for each subject, and the study adhered to
the tenets of the Declaration of Helsinki. Fifty-nine sub-
jects, recruited from the population of students at the
University of Georgia in Athens, Georgia, completed this
12-month, double-blind, randomized, placebo-controlled
supplementation trial. Recruitment for this study occurred
over a six-month period, from November, 2013 – April,
2014. Eighty-four subjects were initially screened, of which
75 met the inclusion criteria. Those subjects who met the
inclusion criteria were randomly assigned, via a random-
number generator weighted 2:2:1 for the two levels of sup-
plement and the placebo, respectively. Due primarily to
non-compliance with the daily supplement regimen, 4
participants from the placebo group, 7 participants from
the 12 mg total group, and 5 participants from the 24
mg total group were removed from the study and
were not included in the final analysis. Subjects were
generally healthy, college-aged (18−25, mean = 21.5
years.; 32 female) non-smokers with a BMI < 27. A
breakdown of subject characteristics and baseline
measures for all groups can be found in Table 1. Sub-
jects were instructed to maintain their current diet;
those that were planning on changing their diet (for
whatever reason) were excluded from consideration
for the trial. For those subjects enrolled in the trial,
stability of diet was evaluated via a non-standardized
fruit and vegetable serving questionnaire. In consider-
ation of macular pigment testing, all subjects had un-
corrected or contact lens-corrected visual acuity of
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20/20 or better in the test (right) eye, and had no
current or previous history of ocular pathology. Mea-
sures of MPOD, DG, and PSR were taken at baseline,
6 months and 12 months.
Macular carotenoid supplementation
As noted above, subjects were randomly assigned to one
of three groups: Group 1 (placebo; n = 10), Group 2 (n =
24; 10 mg L + 1 mg Z + 1 mg MZ per day), or Group 3
(n = 25; 20 mg L + 2 mg Z + 2 mg MZ per day). Pills
were brown-colored, soft gelatin capsules, with L, Z, and
MZ suspended in safflower oil. Subjects were instructed
to ingest one pill with a meal (preferably lunch or din-
ner) every day. Compliance was ensured with weekly
phone calls and pill counts.
Measurement of macular pigment optical density (MPOD)
MPOD was assessed in the right eye with customized
heterochromatic flicker photometry (cHFP [23]). A
densitometer (Macular Metrics Corp., Rehoboth, MA)
described by Wooten et al [24]. was used for this pur-
pose. The densitometer, detailed measurement proce-
dures, and the principle of cHFP have been fully
described in earlier publications [24, 25]. Briefly, subjects
were presented with two superimposed lights that are
temporally alternated in square-wave counterphase. This
creates the perception of a flickering disc of light for the
subject. The peak (550 nm) of the spectral composition
of one of the lights was chosen to bypass the absorption
of MP, and the other (460 nm) was strongly absorbed by
MP. The subject’s task was to adjust the relative radiance
of the two lights until a percept of no flicker (due to per-
ceived isoluminance) was achieved. All other factors
being equal, a subject that requires more short-wave
(i.e., 460 nm) relative to middle-wave (i.e., 550 nm) light
to achieve null flicker has higher MPOD. This task was
performed for the locations of interest within the fovea,
which presumably contain MP, and for a reference loca-
tion in the parafovea that does not (about 7° eccentri-
city). To obtain a measure of MPOD at a given test
locus, the logarithmic ratio of short- to middle-wave
radiance (for null flicker) at the reference location is
subtracted from the corresponding logarithmic ratio
found at the test locus. Although we obtained values for
retinal locations across the MPOD spatial distribution,
the standard 30’ retinal locus proved to account for the
most variance in both the DG and PSR time measures,
and therefore was used for all analyses presented in this
paper. The total time spent on MPOD measurement
was 15 min per session.
Photostress recovery/disability glare
As with MPOD testing, only the right eye of each sub-
ject was tested. A custom apparatus for assessing DG
and PSR time was created to provide sufficient intensity
of light and a uniform spatial distribution with minimal
reliance on optics. A microcontroller, coupled to high-
intensity cool-white LEDs, provided a pulse-width mod-
ulated signal, which permitted the glare and photostress
sources to be held at an adjustable intensity for any
needed duration while maintaining a high degree of lin-
earity and stability in adjustment. The LEDs appear
white by virtue of the phosphor emitting a strong blue
component and a broad yellow-orange component. For
human vision, a mix of blue and yellow sources will
result in a range of whites, denoted “cool” to “warm” e.g.
[26]. For the DG source, a ring of 47 LEDs were placed
on a circuit board with a viewing hole in its center. The
LEDs were arranged in a circular pattern with a 20 mm
radius to create a plane of uniform illumination at the
pupil when held approximately 25 mm from the sub-
ject’s pupil. The photostress source was created by using
45 of the same high-intensity cool-white LEDs arranged
in an approximately square pattern with 5 mm center-
to-center spacing of the LEDs. This arrangement was
used to create a uniform, circular illumination pattern
on an acrylic diffuser that subtended 10° of visual angle
and maintained an illumination of 1200 lux. The driving
microcontroller was given commands over a serial con-
nection to coordinate the intensity of the glare and
photostress sources with a custom-made program that
also produced visual targets for the subject.
Only the right eye of each subject was tested. For both
DG and PSR experiments, the target was an 8 cycle /de-
gree, 15 % Michelson contrast Gabor patch that sub-
tended 2° of visual angle. The Gabor patch was
presented centrally on an LCD monitor. The back-
ground luminance was 20 cd/m2, and appeared
medium-gray to subjects. For the PSR experiment,
subjects were aligned to the optical system via an ad-
justable chin and forehead rest. Once comfortable,







Age (years) 21.71 ± 0.98 21.23 ± 0.95 21.68 ± 1.06
Body mass index (kg/m2) 25.87 ± 1.39 25.49 ± 1.54 25.72 ± 1.61
Male 4 (40 %) 10 (42 %) 13 (52 %)
Female 6 (60 %) 14 (58 %) 12 (48 %)
Servings of fruits,
vegetables/day
1.78 ± 1.52 1.87 ± 1.34 1.77 ± 1.45
Macular pigment optical
density (0.5°)
0.527 ± 0.213 0.488 ± 0.248 0.511 ± 0.202
Disability glare (nominal
intensity)
88.42 ± 58.77 86.02 ± 55.23 91.8 ± 61.66
Photostress recovery time
(seconds)
8.78 ± 5.96 9.11 ± 6.14 9.33 ± 6.39
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subjects were instructed to direct their gaze at the
center of the monitor. The photostress light (1200
lux) was then presented for 8 s. Subjects were asked
to look directly at the light, and try to refrain from
blinking or closing their eyes. After the exposure was
complete, subjects were advised to blink and look in
the center of the monitor for the Gabor target, which
was tilted 45° left or right from vertical. Once the tar-
get was detected, subjects pressed either the left or
right arrow key on a keyboard to indicate which dir-
ection the target was leaning. If correct, subjects were
again presented with the photostress light for 8 s.
This procedure was repeated until a total of 5 recov-
ery thresholds were obtained.
For DG testing, subjects viewed the Gabor patch target
through the ring of LEDs. To guard against visual adap-
tation effects or potential subject bias, the Gabor patch
was made to vertically tilt back and forth 45° every sec-
ond. The experimenter adjusted the intensity of the LED
ring to the point at which the veiling glare was sufficient
to prevent a subject from detecting the tilting of the
Gabor patch. Four thresholds were obtained: two ap-
proaching from below, and two approaching from above
the visibility threshold. The four thresholds were aver-
aged to form the overall DG threshold.
Statistical analysis, blinding procedure
The statistical and graphing program OriginPro 9.3
(Northampton, MA) was used to conduct repeated-
measures ANOVA, Pearson product-moment correla-
tions, and generate figures for the manuscript. Assuming
a placebo group of n = 10, an a priori power calculation
using a 20 % change in glare performance in treatment
groups, coupled with a standard deviation of 20 %, and
α = 0.05 indicated that both 12 and 24 mg L/Z groups
required 25 subjects to detect effects (if present). We
assumed an attrition rate of roughly 20 %, and therefore
enrolled 75 subjects. As noted above, 59 completed the
trial.
The randomization sequence was generated by the
study coordinator (NTS), who performed random alloca-
tion to the three study groups. The study investigator
(JMS) received a box of supplements labeled only with
the participant identification number. Upon completion
of the study, the randomization sequence was revealed,
and data analysis ensued.
Results
Main effects
Table 2 presents main effects data for all groups at both
6 and 12 months. For main effects and correlational ana-
lyses, the first in the series of 5 PSR measures was used.
Additional analyses of repeated exposures and PSR times
are presented in “Dynamics of Photostress Recovery and
the ‘Fatigue Function’” below.
Repeated-measures ANOVAs determined significant
changes versus placebo for MPOD, PSR, and DG thresh-
olds (see Fig. 1) in both active supplement groups
between baseline and 6 months (p < 0.05 for all), and be-
tween 6 and 12 months, save PSR for the 24 mg L + Z +
MZ group (p < 0.05 for all). The placebo group did not
change appreciably in any of the outcome measures
throughout the study (see Fig. 1). Additionally, there
were no between-groups effects determined for the 12
mg L + Z +MZ vs. 24 mg L + Z +MZ groups in any of
the outcome measures.
Correlations
At each assessment point throughout the study, several
measures were found to be significantly correlated. At
baseline, DG thresholds were significantly correlated to
MPOD levels (r = -0.444; p = 0.0021; see Fig. 2). Subjects’
PSR thresholds were also significantly correlated to
MPOD at baseline (r = -0.56; p < 0.001; see Fig. 3).
Changes in PSR were directly related to changes in
DG, as determined by the correlation between the
two (r = -0.534; p < 0.001; see Fig. 4).
Dynamics of photostress recovery and the “fatigue
function”
As noted in the Methods section, subjects completed a
sequence of 5 PSR threshold measures per trial. Upon
analysis of the data generated by this procedure (hereto-
fore referred to as the “fatigue function”), a pattern be-
came evident where, as a function of MPOD, the slope
of the fatigue function became more shallow (i.e., recov-
ery times were more stable with successive exposures).
The baseline fatigue functions for four subjects, with
progressively higher MPOD, are presented in Fig. 5.
After 12 months, an increase in MPOD resulted in de-
creased slopes for fatigue functions for subjects in both
active supplement groups. The change in slope was
found to be significantly more shallow, compared with
placebo (F = 6.74; p < 0.001). Tukey’s posthoc test re-
vealed no difference in slope change between 12 mg vs.
24 mg groups.
Discussion
The basis for many effects of MPOD on visual perform-
ance would appear to be selective filtering of the short-
wavelength band of the visible spectrum. This has been
shown to be especially true for visual performance and
comfort in glare, and certainly applies to chromatic con-
trast and vision through blue haze. The ability of the
MCs to influence the visual physiology of the retina and
thereby impact parameters of visual performance such
as dark adaptation, contrast sensitivity, or temporal
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processing speed, however, has only become appreciated
recently.
The results of our study, particularly those from the
PSR portion, are illustrative of effects elicited by both
filtering of light by MPOD, and by retinal physiology
enhancement by the MCs. For example, in absolute
terms, those with higher MPOD generally had faster
PSR times – this was true for each of the 5 exposures
and recoveries – but speed of visual recovery was
markedly faster and more consistent with successive
exposures for those with higher MPOD (see Fig. 5). The
repeated exposures that were used to generate the
“fatigue functions” in our investigation provide an ap-
proximation, albeit crude, of what the retina must do on
a continual basis to give rise to vision. The literal hun-
dreds of millions of physiological steps [27] that must be
carried out every second that the retina is exposed to
light reflected off a complex visual scene must be com-
pleted efficiently otherwise, the retina simply will not be
able to “keep up” with incoming photons. This inability
to keep pace with the demands of light manifests as a
temporary loss of vision, and is actually quite common:
an object whose light level is below the current state of
light adaptation will not be detectable, until the visual
Table 2 Data for main effects at each measurement point in the trial, by group. Lutein and total zeaxanthin serum data are also
included
Group Measure Baseline 6 months 12 months
Placebo (n = 10) MPOD 0.527 ± 0.213 0.558 ± 0.222 0.564 ± 0.237
Disability Glare 88.42 ± 58.77 90.63 ± 57.47 91.96 ± 59.12
Photostress recovery (mins) 8.78 ± 5.96 8.84 ± 6.12 8.71 ± 5.79
Serum L (μg/mL) 0.34 ± 0.07 0.35 ± 0.07 0.34 ± 0.08
Serum total Z (μg/mL) 0.13 ± 0.02 0.115 ± 0.03 0.125 ± 0.02
12 mg (n = 24) MPOD 0.488 ± 0.248 0.586 ± 0.266* 0.654 ± 0.282**
Disability Glare 86.02 ± 55.23 113.55 ± 60.11* 120.43 ± 64.52**
Photostress recovery (mins) 9.11 ± 6.14 7.65 ± 5.41* 6.92 ± 5.09**
Serum L (μg/mL) 0.40 ± 0.08 2.24 ± 0.22* 2.16 ± 0.20**
Serum total Z (μg/mL) 0.10 ± 0.014 0.29 ± 0.03* 0.27 ± 0.03**
24 mg (n = 25) MPOD 0.511 ± 0.202 0.634 ± 0.271* 0.685 ± 0.289**
Disability Glare 91.8 ± 61.66 123.01 ± 67.43* 128.52 ± 69.96**
Photostress recovery (mins) 9.33 ± 6.39 7.28 ± 5.86* 6.99 ± 5.56*
Serum L (μg/mL) 0.33 ± 0.05 3.25 ± 0.27* 3.29 ± 0.29**
Serum total Z (μg/mL) 0.13 ± 0.01 0.51 ± 0.06* 0.53 ± 0.06**
Based on repeated-measures ANOVA, single asterisk = significant difference from baseline and placebo (p < 0.05); double asterisk = significant difference
from baseline, 6-month measure, and placebo (p < 0.05)
Fig. 1 Percent change from baseline at 6 and 12 months for all
outcome measures. Error bars are ± 1 SD. Single asterisk denotes
significant difference from baseline and placebo (p < 0.05 level);
double asterisk denotes significant differences from baseline,
6-month measure, and placebo (p < 0.05 level) Fig. 2 Glare ring intensity setting as a function of MPOD, at baseline
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system (via the aforementioned physiological reactions)
recovers to a lower state of adaptation. In fact, maintain-
ing any state of visual adaptation requires a dynamic
equilibrium in which the demand for resources by
incoming light must be met by efficient physiological
processing. With regard to our PSR results, the point
here is that those with higher MPOD appear to have
significantly more efficient physiological processing in
their retinas.
One could reasonably argue that the differences seen
for high vs. low MPOD for the first exposure/PSR time
measure is primarily influenced by light filtration by
MPOD. But the pattern for subsequent exposures is sug-
gestive of a physiological component. Otherwise, each
PSR recovery time would be very similar, regardless of
MPOD. That the pattern of responses for those with
high MPOD is relatively flat suggests that their visual
systems are effectively able to maintain an advantageous
state of adaptation. In the short term, this would be
beneficial if exposed to a bright flash or reflection of
bright light; recovery of vision would be relatively quick.
In the long term (say, over the period of one day), this
may result in less visual fatigue, or perhaps eye strain.
Future studies could examine these outcomes.
The results of the DG portion of the study are consist-
ent with most previous investigations of this phenomenon
e.g. [10, 18–21]. There appears, however, to be significant
variability among subjects in DG performance, as
evidenced by the wide, homoscedastic spread in the data
(see Fig. 2). This contrasts with the PSR data, which are
suggestive of a curvilinear function, and fall more closely
to the line of best fit (see Fig. 3). Despite both PSR and
DG correlations being significant, this pattern in the data
(and the larger Pearson’s r value) indicates that MPOD
accounts for more of the variability in PSR time than in
DG thresholds. Alternative factors that may impact DG
performance include iris pigmentation (i.e., lighter irides
transmit more light, and presumably would lead to greater
intraocular scatter), how inset the eyes are relative to
brow, and perhaps skin pigmentation (wherein pale skin
would tend to reflect more light into the eyes than dark
skin). Although we obtained iris color data, it was difficult
to isolate effects based solely on this single factor, as those
within any iris color group exhibited significant variability
in other dimensions, such as MPOD or skin pigmentation.
Moreover, despite statistically controlling for these factors,
no significant contribution to DG performance was deter-
mined for iris color. Future studies designed to isolate
these variables would be best suited to provide conclusive
evidence on this matter.
The breadth of the impact of the MCs in general, and
of MPOD in the retina, continues to expand. The results
of our study indicate contributions to visual
Fig. 3 PSR time as a function of MPOD, at baseline
Fig. 4 Change between baseline and 12 month measures in PSR
time, as a function of the same change for DG thresholds. Symbol
key for groups noted in legend
Fig. 5 PSR “fatigue functions” at baseline for four subjects with
different MPOD. Functions fit with B-spline interpolation. See text
for explanation
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performance that include aspects of optical filtering and
enhancement of retinal metabolism. Although our
effects were strong, and correlated to increases in
MPOD, we found no differences in any outcome meas-
ure between our two dose levels. This may have been
due to differences in absorption of the MCs, or in
retinal uptake and deposition. Indeed, there were
seven subjects in the 12 mg group that responded
very strongly to the supplement – increasing by at
least 0.25 OD over the 12-month study period – and
there were no “non-responders” (OD increase < 0.05)
in this group. By contrast, only five of the subjects in
the 24 mg group increased by 0.25 OD or more, and
there were three non-responders in this group. There
are several possible physiological steps, including
transport [28], binding [29], and/or perhaps demand
for these carotenoids for more immediate uses, such
as the reduction of systemic inflammation or oxida-
tion [30], whereby the ultimate function and use of
macular carotenoids could be enhanced or compromised.
Given all of the health and performance benefits derived
from increased systemic and local concentrations of these
carotenoids, determining the factors that contribute to
absorption, transport, binding, and deposition is perhaps
the most urgent scientific question in this area.
Conclusions
Based on the results of this study, it is clear that
increases in MPOD lead to significant improvements in
PSR times and DG thresholds. These results are sup-
ported further by the correlations seen at baseline
between MPOD and both PSR and DG thresholds. The
asymptotic shape of the repeated-exposure PSR curves
suggests that increases in MPOD (and indeed higher
MPOD in general) produce more consistent steady-state
visual performance in bright light conditions. This find-
ing is important in considering the demands placed
upon vision in bright light situations, and could plausibly
be suggestive of potential improvements in overall out-
door visual performance, and safety during bright light-
ing conditions (e.g., driving at night while facing
oncoming headlights). Based on our findings, it appears
that DG and PSR performance are not only related to
each other, but also have MPOD as a mediating variable
in common. The mechanisms for the effects on DG and
PSR, however, may be derived from different characteris-
tics of MP; they may involve both or either the optical
filtering and biochemical (antioxidant) properties of MP.
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